Matthew Mayaki net worth
Quick answer
Matthew Mayaki's estimated net worth is $20.4M (range $14.28M – $30.6M) as of 2026. Matthew Mayaki is CTO at Reliance Health. Reliance Health valuation.
Matthew Mayaki is CTO at Reliance Health (YC W17). Independent Entrepreneurial Check model estimate from public YC data.
At a glance
- Company status: Active
- Education: University of Illinois at Urbana-Champaign
- Region: Unspecified
- Industries: Healthcare, Healthcare Services
- Team size: 384
- Website: https://www.getreliancehealth.com
Who is Matthew Mayaki?
Matthew Mayaki is a co-founder of Reliance Health, an organization focused on transforming healthcare in Africa through technology and innovation.
Highlights:
- University of Illinois at Urbana-Champaign
- Reliance Health
- Y Combinator W17
About Reliance Health
Reliance Health uses technology to make quality healthcare delightful, affordable and accessible in emerging markets. Through an integrated approach that includes affordable health insurance, telemedicine and a combination of partner and proprietary healthcare facilities, Reliance Health offers innovative healthcare solutions that meet the needs of emerging markets including Nigeria, Egypt and growing
FAQ: Matthew Mayaki net worth and Reliance Health valuation
What is Matthew Mayaki's net worth?
Matthew Mayaki's estimated net worth is $20.4M (range $14.28M – $30.6M) as of 2026. Matthew Mayaki is CTO at Reliance Health. Entrepreneurial Check publishes an independent model-based estimate from public company and role data. Not verified net worth, and Entrepreneurial Check is not affiliated with Y Combinator or the profiled companies.
What is Reliance Health valuation?
Reliance Health's estimated valuation on Entrepreneurial Check is $400.0M. That valuation, or a disclosed round when one is public, is the source for the paper-wealth estimate. Independent model output — not a verified appraisal or official mark.
What is Matthew Mayaki's role?
Matthew Mayaki is CTO at Reliance Health, a Y Combinator-backed startup (batch W17).